Vycor Medical Reports 31% Increase in Third-Quarter Revenue

Reuters

2025/11/15

Vycor Medical Reports 31% Increase in Third-Quarter Revenue

Vycor Medical Inc. reported revenue of $513.8 thousand for the three months ended September 30, 2025, a 31.4% increase from $390.9 thousand in the same period in 2024. The Vycor Medical division generated $492.1 thousand, up 32% year over year, primarily due to growth in the US. The NovaVision division, still in development, recorded sales of $21.7 thousand, up from $18.0 thousand in 2024. Gross profit for the quarter was $451.9 thousand with a gross margin of 88%, compared to $354.1 thousand and a 90% margin in 2024, with the margin decrease attributed to validation and shipping costs of new production runs. For the nine months ended September 30, 2025, the company reported revenue of $1.45 million, a 27.5% increase from $1.13 million in 2024. Vycor Medical division revenue rose 29.1% to $1.39 million, mainly due to international market growth. NovaVision sales were $54.1 thousand compared to $55.5 thousand in 2024. The gross profit margin for the period was 84%, down from 90% in 2024, due to higher costs and international sales mix.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vycor Medical Inc. published the original content used to generate this news brief on November 14, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2583688606"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583688606\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583688606?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-15 00:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583688606","market":"us","top_or_hot":-1,"title":"Vycor Medical Reports 31% Increase in Third-Quarter Revenue","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vycor Medical Reports 31% Increase in Third-Quarter Revenue\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vycor Medical Inc. reported revenue of $513.8 thousand for the three months ended September 30, 2025, a 31.4% increase from $390.9 thousand in the same period in 2024. The Vycor Medical division generated $492.1 thousand, up 32% year over year, primarily due to growth in the US. The NovaVision division, still in development, recorded sales of $21.7 thousand, up from $18.0 thousand in 2024. Gross profit for the quarter was $451.9 thousand with a gross margin of 88%, compared to $354.1 thousand and a 90% margin in 2024, with the margin decrease attributed to validation and shipping costs of new production runs. For the nine months ended September 30, 2025, the company reported revenue of $1.45 million, a 27.5% increase from $1.13 million in 2024. Vycor Medical division revenue rose 29.1% to $1.39 million, mainly due to international market growth. NovaVision sales were $54.1 thousand compared to $55.5 thousand in 2024. The gross profit margin for the period was 84%, down from 90% in 2024, due to higher costs and international sales mix.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vycor Medical Inc. published the original content used to generate this news brief on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vycor Medical Reports 31% Increase in Third-Quarter Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVycor Medical Reports 31% Increase in Third-Quarter Revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-15 00:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vycor Medical Reports 31% Increase in Third-Quarter Revenue\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vycor Medical Inc. reported revenue of $513.8 thousand for the three months ended September 30, 2025, a 31.4% increase from $390.9 thousand in the same period in 2024. The Vycor Medical division generated $492.1 thousand, up 32% year over year, primarily due to growth in the US. The NovaVision division, still in development, recorded sales of $21.7 thousand, up from $18.0 thousand in 2024. Gross profit for the quarter was $451.9 thousand with a gross margin of 88%, compared to $354.1 thousand and a 90% margin in 2024, with the margin decrease attributed to validation and shipping costs of new production runs. For the nine months ended September 30, 2025, the company reported revenue of $1.45 million, a 27.5% increase from $1.13 million in 2024. Vycor Medical division revenue rose 29.1% to $1.39 million, mainly due to international market growth. NovaVision sales were $54.1 thousand compared to $55.5 thousand in 2024. The gross profit margin for the period was 84%, down from 90% in 2024, due to higher costs and international sales mix.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vycor Medical Inc. published the original content used to generate this news brief on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VYCO","symbol_name":"Vycor Medical, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDLwqWyV:1","article_id":"2583688606","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583688606","pubTimestamp":1763137506,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vycor Medical Inc. reported revenue of $513.8 thousand for the three months ended September 30, 2025, a 31.4% increase from $390.9 thousand in the same period in 2024. The Vycor Medical division generated $492.1 thousand, up 32% year over year, primarily due to growth in the US. The NovaVision division, still in development, recorded sales of $21.7 thousand, up from $18.0 thousand in 2024. Gross profit for the quarter was $451.9 thousand with a gross margin of 88%, compared to $354.1 thousand and a 90% margin in 2024, with the margin decrease attributed to validation and shipping costs of new production runs. For the nine months ended September 30, 2025, the company reported revenue of $1.45 million, a 27.5% increase from $1.13 million in 2024. Vycor Medical division revenue rose 29.1% to $1.39 million, mainly due to international market growth. NovaVision sales were $54.1 thousand compared to $55.5 thousand in 2024. The gross profit margin for the period was 84%, down from 90% in 2024","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VYCO":"Vycor Medical, Inc.","BK4198":"医疗保健用品"},"translate_title":"Vycor Medical报告第三季度收入增长31%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VYCO":0.9},"content_text":"Vycor Medical Reports 31% Increase in Third-Quarter Revenue\n    \n\n        Vycor Medical Inc. reported revenue of $513.8 thousand for the three months ended September 30, 2025, a 31.4% increase from $390.9 thousand in the same period in 2024. The Vycor Medical division generated $492.1 thousand, up 32% year over year, primarily due to growth in the US. The NovaVision division, still in development, recorded sales of $21.7 thousand, up from $18.0 thousand in 2024. Gross profit for the quarter was $451.9 thousand with a gross margin of 88%, compared to $354.1 thousand and a 90% margin in 2024, with the margin decrease attributed to validation and shipping costs of new production runs. For the nine months ended September 30, 2025, the company reported revenue of $1.45 million, a 27.5% increase from $1.13 million in 2024. Vycor Medical division revenue rose 29.1% to $1.39 million, mainly due to international market growth. NovaVision sales were $54.1 thousand compared to $55.5 thousand in 2024. The gross profit margin for the period was 84%, down from 90% in 2024, due to higher costs and international sales mix.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vycor Medical Inc. published the original content used to generate this news brief on November 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}